文献速递白血病MDS 与骨髓增殖性肿瘤

继发性急性髓系白血病的临床基因组学探究:当代治疗的反应与结局

Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies.
PubMed 文献 · Am J Hematol · 2025-02-08

该研究定义未治疗临床继发性AML(CS-AML,n=133)和基因组继发性AML(GS-AML,n=389),比较两组及与纯新发AML的缓解和生存。CS-AML与GS-AML的中位无复发生存期(11.9 vs 12.4个月,p=0.36)和总生存期(11.6 vs 14.4个月,p=0.75)相似。仅骨髓增生异常相关突变(MRM)的GS-AML接受低强度治疗+维奈克拉方案的总生存期优于MRM±骨髓增生异常相关细胞遗传学(MRC)者。

要点

  • 未治疗CS-AML与GS-AML的中位RFS和OS无显著差异。
  • 仅MRM的GS-AML接受低强度治疗+维奈克拉的OS优于MRM±MRC者。
  • 不良细胞遗传学是预测生存的最强预后变量。

核心结论

  • 新诊断AML中,MRM驱动的基因组起源在维奈克拉为基础治疗下预后意义似乎小于细胞遗传学驱动的起源。

研究设计与样本

  • 研究纳入新诊断AML患者,定义未治疗CS-AML为有MDS或MDS-MPN病史且未暴露于去甲基化药物或化疗者(n=133),GS-AML为有MRC或MRM且无已知前驱髓系肿瘤或非髓系肿瘤放化疗史者(n=389)。

主要发现

  • 未治疗CS-AML与GS-AML的中位RFS为11.9 vs 12.4个月(p=0.36),中位OS为11.6 vs 14.4个月(p=0.75)。
  • 接受低强度治疗和维奈克拉方案时,CS-AML与GS-AML的RFS和OS无差异,但两者均劣于无继发性基因组学的纯新发AML(pure DN-AML)。
  • 仅MRM的GS-AML接受低强度治疗+维奈克拉方案,相比MRM±MRC者,RFS为19.5 vs 6.8个月(p<0.01),OS为29.6 vs 8.4个月(p<0.01);与接受低强度治疗+维奈克拉的纯新发AML相比,RFS(29.8个月,p=0.48)和OS(32.0个月,p=0.48)相似。
  • 接受低强度治疗+维奈克拉方案患者的多因素分析中,未治疗CS-AML(vs GS-AML)、不良细胞遗传学和ELN 2024不良风险疾病(突变TP53)与更高的死亡风险相关。
  • 不良细胞遗传学是预测生存的最强预后变量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ontogeny of acute myeloid leukemia (AML) provides prognostic information, however closer interrogation with respect to AML characteristics, genomics, and various treatments are warranted. We defined untreated clinical secondary (CS) AML as AML with a diagnosis of antecedent myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MDS-MPN) without exposure to hypomethylating agents or chemotherapy; genomic secondary (GS) AML included patients with myelodysplasia related cytogenetics (MRC) or myelodysplasia related mutations (MRM) without a known antecedent myeloid neoplasm or prior chemo-radiotherapy for non-myeloid neoplasms. Among newly diagnosed AML patients classified as untreated CS-AML (n = 133) or GS-AML (n = 389), median relapse-free survival (RFS) (11.9 vs. 12.4 months, p = 0.36) and overall survival (OS) (11.6 vs. 14.4 months, p = 0.75) were similar. No difference in RFS and OS between these groups treated with low-intensity therapy (LIT) and venetoclax regimens was seen, but both were inferior to de novo (DN) AML without secondary-type genomics (pure DN-AML). GS-AML defined by the presence of only MRM had superior OS compared with MRM ± MRC with LIT+ venetoclax therapy (RFS 19.5 vs. 6.8 months [p < 0.01] and OS 29.6 vs. 8.4 [p < 0.01]) and had similar RFS (29.8 months, p = 0.48) and OS (32.0 months, p = 0.48) to pure DN-AML treated with LIT+ venetoclax. On multivariate analysis in patients treated with LIT+ venetoclax, untreated CS-AML (vs. GS-AML), adverse cytogenetics and ELN 2024 adverse-risk disease (mutated TP53) were associated with higher hazard of death. Adverse cytogenetics was the strongest prognostic variable predicting survival. Mutation-driven genomic ontogeny of newly diagnosed AML with MRM appears less prognostic than cytogenetic-driven ontogeny with venetoclax-based therapy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Senapati J, Loghavi S, Marvin-Peek J, et al. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. Am J Hematol. 2025. PMID: 39921561. doi:10.1002/ajh.27628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。